{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T05:30:24Z","timestamp":1739338224992,"version":"3.37.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2009,8,20]],"date-time":"2009-08-20T00:00:00Z","timestamp":1250726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2009,10]]},"DOI":"10.1007\/s00482-009-0824-3","type":"journal-article","created":{"date-parts":[[2009,8,18]],"date-time":"2009-08-18T13:27:04Z","timestamp":1250602024000},"page":"471-478","source":"Crossref","is-referenced-by-count":5,"title":["Methylnaltrexon","Methylnaltrexone"],"prefix":"10.1007","volume":"23","author":[{"given":"D.","family":"Chappell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Conzen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,8,20]]},"reference":[{"key":"824_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0885-3924(97)00276-5","volume":"15","author":"Agra","year":"1998","unstructured":"Agra Y, Sacristan A, Gonzalez M et al (1998) Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J Pain Symptom Manage 15:1\u20137","journal-title":"J Pain Symptom Manage"},{"key":"824_CR2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/SPC.0b013e3282f04e0c","volume":"1","author":"Ahmedzai","year":"2007","unstructured":"Ahmedzai SH, Boland J (2007) Opioids for chronic pain: molecular and genomic basis of actions and adverse effects. Curr Opin Support Palliat Care 1:117\u2013125","journal-title":"Curr Opin Support Palliat Care"},{"key":"824_CR3","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1136\/bmj.322.7295.1154","volume":"322","author":"Allan","year":"2001","unstructured":"Allan L, Hays H, Jensen NH et al (2001) Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ 322:1154\u20131158","journal-title":"BMJ"},{"key":"824_CR4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1213\/01.ANE.0000097168.32472.0D","volume":"98","author":"Blunk","year":"2004","unstructured":"Blunk JA, Schmelz M, Zeck S et al (2004) Opioid-induced mast cell activation and vascular responses is not mediated by mu-opioid receptors: an in vivo microdialysis study in human skin. Anesth Analg 98:364\u2013370","journal-title":"Anesth Analg"},{"key":"824_CR5","first-page":"6","volume":"Care","author":"Boland","year":"2008","unstructured":"Boland J, Ahmedzai SH (2008) Targeted management of opioid-induced constipation: the role of the novel, peripherally acting, mu-opioid receptor antagonist methylnaltrexone bromide. Eur J Pall Care (Suppl):6\u201311","journal-title":"Eur J Pall"},{"key":"824_CR6","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1200\/JCO.1992.10.1.149","volume":"10","author":"Brescia","year":"1992","unstructured":"Brescia FJ, Portenoy RK, Ryan M et al (1992) Pain, opioid use, and survival in hospitalized patients with advanced cancer. J Clin Oncol 10:149\u2013155","journal-title":"J Clin Oncol"},{"key":"824_CR7","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00101-008-1420-0","volume":"57","author":"Chappell","year":"2008","unstructured":"Chappell D, Conzen P (2008) Therapy of opioid-induced constipation. Anaesthesist 57:1011\u20131014","journal-title":"Anaesthesist"},{"key":"824_CR8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/cc6930","volume":"12","author":"Chappell","year":"2008","unstructured":"Chappell D, Rehm M, Conzen P (2008) Opioid-induced constipation in intensive care patients: relief in sight? Crit Care 12:161","journal-title":"Crit Care"},{"key":"824_CR9","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","volume":"19","author":"Cherny","year":"2001","unstructured":"Cherny N, Ripamonti C, Pereira J et al (2001) Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol 19:2542\u20132554","journal-title":"J Clin Oncol"},{"key":"824_CR10","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s00520-007-0373-1","volume":"16","author":"Droney","year":"2008","unstructured":"Droney J, Ross J, Gretton S et al (2008) Constipation in cancer patients on morphine. Support Care Cancer 16:453\u2013459","journal-title":"Support Care Cancer"},{"key":"824_CR11","first-page":"5","volume":"7","author":"Fainsinger","year":"1991","unstructured":"Fainsinger R, Miller MJ, Bruera E et al (1991) Symptom control during the last week of life on a palliative care unit. J Palliat Care 7:5\u201311","journal-title":"J Palliat Care"},{"key":"824_CR12","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S0022-3565(25)13046-2","volume":"253","author":"Jiang","year":"1990","unstructured":"Jiang Q, Sheldon RJ, Porreca F (1990) Opioid modulation of basal intestinal fluid transport in the mouse: actions at central, but not intestinal, sites. J Pharmacol Exp Ther 253:784\u2013790","journal-title":"J Pharmacol Exp Ther"},{"key":"824_CR13","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00520-003-0525-x","volume":"11","author":"Klaschik","year":"2003","unstructured":"Klaschik E, Nauck F, Ostgathe C (2003) Constipation \u2013 modern laxative therapy. Support Care Cancer 11:679\u2013685","journal-title":"Support Care Cancer"},{"key":"824_CR14","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0885-3924(00)00167-6","volume":"20","author":"Klepstad","year":"2000","unstructured":"Klepstad P, Borchgrevink PC, Kaasa S (2000) Effects on cancer patients\u2018 health-related quality of life after the start of morphine therapy. J Pain Symptom Manage 20:19\u201326","journal-title":"J Pain Symptom Manage"},{"key":"824_CR15","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003495-200363070-00003","volume":"63","author":"Kurz","year":"2003","unstructured":"Kurz A, Sessler DI (2003) Opioid-induced bowel dysfunction: pathophysiology and potential new therapies. Drugs 63:649\u2013671","journal-title":"Drugs"},{"key":"824_CR16","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/S0885-3924(01)00369-4","volume":"23","author":"Liu","year":"2002","unstructured":"Liu M, Wittbrodt E (2002) Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 23:48\u201353","journal-title":"J Pain Symptom Manage"},{"key":"824_CR17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1067\/mcp.2001.112680","volume":"69","author":"Liu","year":"2001","unstructured":"Liu SS, Hodgson PS, Carpenter RL, Fricke JR Jr (2001) ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 69:66\u201371","journal-title":"Clin Pharmacol Ther"},{"key":"824_CR18","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejpain.2008.06.012","volume":"13","author":"Meissner","year":"2008","unstructured":"Meissner W, Leyendecker P, Mueller-Lissner S et al (2008) A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 13:56\u201364","journal-title":"Eur J Pain"},{"key":"824_CR19","doi-asserted-by":"crossref","first-page":"R1046","DOI":"10.1186\/ar1782","volume":"7","author":"Moore","year":"2005","unstructured":"Moore RA, McQuay HJ (2005) Prevalence of opioid adverse events in chronic nonmalignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 7:R1046\u2013R1051","journal-title":"Arthritis Res Ther"},{"key":"824_CR20","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/bja\/aeg275","volume":"91","author":"Mostafa","year":"2003","unstructured":"Mostafa SM, Bhandari S, Ritchie G et al (2003) Constipation and its implications in the critically ill patient. Br J Anaesth 91:815\u2013819","journal-title":"Br J Anaesth"},{"key":"824_CR21","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00482-005-0431-x","volume":"19","author":"Oeltjenbruns","year":"2005","unstructured":"Oeltjenbruns J, Sch\u00e4fer N (2005) Anwendungsm\u00f6glichkeiten und Stellenwert der peripheren Opioidanalgesie. Schmerz 19:447\u2013455","journal-title":"Schmerz"},{"key":"824_CR22","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1055\/s-0028-1104754","volume":"37","author":"Osterbrink","year":"2008","unstructured":"Osterbrink J, Haas U (2008) Die opioidinduzierte Obstipation und ihre Behandlungsm\u00f6glichkeiten. Klinikarzt 37:527\u2013530","journal-title":"Klinikarzt"},{"key":"824_CR23","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10354-008-0589-9","volume":"158","author":"Osterbrink","year":"2008","unstructured":"Osterbrink J, Haas U (2008) Opioid-induced bowel dysfunction: a literature analysis on pathophysiology and treatment. Wien Med Wochenschr 158:621\u2013626","journal-title":"Wien Med Wochenschr"},{"key":"824_CR24","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/j.1742-1241.2007.01415.x","volume":"61","author":"Panchal","year":"2007","unstructured":"Panchal SJ, Muller-Schwefe P, Wurzelmann JI (2007) Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract 61:1181\u20131187","journal-title":"Int J Clin Pract"},{"key":"824_CR25","doi-asserted-by":"crossref","first-page":"11S","DOI":"10.1016\/S0002-9610(01)00782-6","volume":"182","author":"Pappagallo","year":"2001","unstructured":"Pappagallo M (2001) Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182:11S\u201318S","journal-title":"Am J Surg"},{"key":"824_CR26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1191\/026921600671594561","volume":"14","author":"Radbruch","year":"2000","unstructured":"Radbruch L, Sabatowski R, Loick G et al (2000) Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine. Palliat Med 14:111\u2013119","journal-title":"Palliat Med"},{"key":"824_CR27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S0885-3924(98)00080-3","volume":"16","author":"Ramesh","year":"1998","unstructured":"Ramesh PR, Kumar KS, Rajagopal MR et al (1998) Managing morphine-induced constipation: a controlled comparison of an Ayurvedic formulation and senna. J Pain Symptom Manage 16:240\u2013244","journal-title":"J Pain Symptom Manage"},{"key":"824_CR28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-230X-6-19","volume":"6","author":"Reintam","year":"2006","unstructured":"Reintam A, Parm P, Redlich U et al (2006) Gastrointestinal failure in intensive care: a retrospective clinical study in three different intensive care units in Germany and Estonia. BMC Gastroenterol 6:19","journal-title":"BMC Gastroenterol"},{"key":"824_CR29","doi-asserted-by":"crossref","first-page":"357","DOI":"10.36076\/ppj.2007\/10\/357","volume":"10","author":"Ruan","year":"2007","unstructured":"Ruan X (2007) Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician 10:357\u2013366","journal-title":"Pain Physician"},{"key":"824_CR30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1007\/s00482-004-0325-3","volume":"19","author":"Schwarzer","year":"2005","unstructured":"Schwarzer A, Nauck F, Klaschik E (2005) Strong opioids and constipation. Schmerz 19:214\u2013219","journal-title":"Schmerz"},{"key":"824_CR31","first-page":"39","volume":"7","author":"Slatkin","year":"2009","unstructured":"Slatkin N, Thomas J, Lipman AG et al (2009) Methylnaltrexone for treatment of opioidinduced constipation in advanced illness patients. J Support Oncol 7:39\u201346","journal-title":"J Support Oncol"},{"key":"824_CR32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0166-2236(00)01611-8","volume":"23","author":"Stefano","year":"2000","unstructured":"Stefano GB, Goumon Y, Casares F et al (2000) Endogenous morphine. Trends Neurosci 23:436\u2013442","journal-title":"Trends Neurosci"},{"key":"824_CR33","first-page":"279","volume":"55","author":"Stefano","year":"2004","unstructured":"Stefano GB, Zhu W, Cadet P et al (2004) Morphine enhances nitric oxide release in the mammalian gastrointestinal tract via the micro (3) opiate receptor subtype: a hormonal role for endogenous morphine. J Physiol Pharmacol 55(3):279\u2013288","journal-title":"J Physiol Pharmacol"},{"key":"824_CR34","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/nm908","volume":"9","author":"Stein","year":"2003","unstructured":"Stein C, Sch\u00e4fer M, Machelska H (2003) Attacking pain at its source: new perspectives on opioids. Nat Med 9:1003\u20131008","journal-title":"Nat Med"},{"key":"824_CR35","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0304-3959(98)00208-5","volume":"80","author":"Suzuki","year":"1999","unstructured":"Suzuki R, Chapman V, Dickenson AH (1999) The effectiveness of spinal and systemic morphine on rat dorsal horn neuronal responses in the spinal nerve ligation model of neuropathic pain. Pain 80:215\u2013228","journal-title":"Pain"},{"key":"824_CR36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/026921639000400406","volume":"4","author":"Sykes","year":"1990","unstructured":"Sykes N (1990) Methods of assessment of bowel function in patients with advanced cancer. Palliat Med 4:287\u2013292","journal-title":"Palliat Med"},{"key":"824_CR37","first-page":"1","volume":"Care","author":"Sykes","year":"2008","unstructured":"Sykes N (2008) Opioid induced constipation. Eur J Pall Care (Suppl):1\u20135","journal-title":"Eur J Pall"},{"key":"824_CR38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1191\/026921698674125048","volume":"12","author":"Sykes","year":"1998","unstructured":"Sykes NP (1998) The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12:375\u2013382","journal-title":"Palliat Med"},{"unstructured":"The European Pain in Cancer survey (2009) http:\/\/www.paineurope.com\/index.php?q=en\/book_page\/epic_survey","key":"824_CR39"},{"key":"824_CR40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jpainsymman.2007.01.017","volume":"35","author":"Thomas","year":"2008","unstructured":"Thomas J (2008) Opioid-induced bowel dysfunction. J Pain Symptom Manage 35:103\u2013113","journal-title":"J Pain Symptom Manage"},{"key":"824_CR41","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1056\/NEJMoa0707377","volume":"358","author":"Thomas","year":"2008","unstructured":"Thomas J, Karver S, Cooney GA et al (2008) Methylnaltrexone for opioid-induced constipation in advanced illness. N Engl J Med 358:2332\u20132343","journal-title":"N Engl J Med"},{"key":"824_CR42","first-page":"II43","volume":"45","author":"Thompson","year":"1999","unstructured":"Thompson WG, Longstreth GF, Drossman DA et al (1999) Functional bowel disorders and functional abdominal pain. Gut 45 (Suppl 2):II43\u2013II47","journal-title":"Gut"},{"key":"824_CR43","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1191\/0269216306pm1135oa","volume":"20","author":"Twycross","year":"2006","unstructured":"Twycross RG, McNamara P, Schuijt C et al (2006) Sodium picosulfate in opioid-induced constipation: results of an open-label, prospective, dose-ranging study. Palliat Med 20:419\u2013423","journal-title":"Palliat Med"},{"key":"824_CR44","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00134-006-0175-9","volume":"32","author":"van","year":"2006","unstructured":"van der Spoel JI, Schultz MJ, van der Voort PH, de Jonge E (2006) Influence of severity of illness, medication and selective decontamination on defecation. Intensive Care Med 32:875\u2013880","journal-title":"Intensive Care Med"},{"unstructured":"Wellmann C, Wilson G, Israel R (2008) Methylnaltrexone in the treatment of opioidinduced constipation in patients with advanced illness: results of two Phase 3 trials. Palliative Medicine 12th International Symposium. Scotsdale, AZ, USA (Poster)","key":"824_CR45"},{"key":"824_CR46","first-page":"137","volume":"Clin","author":"Wigzell","year":"1969","unstructured":"Wigzell FW (1969) The health of nonagenarians. Gerontol Clin (Basel) 11:137\u2013144","journal-title":"Gerontol"},{"key":"824_CR47","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/104990910502200511","volume":"22","author":"Wirz","year":"2005","unstructured":"Wirz S, Klaschik E (2005) Management of constipation in palliative care patients undergoing opioid therapy: is polyethylene glycol an option? Am J Hosp Palliat Care 22:375\u2013381","journal-title":"Am J Hosp Palliat Care"},{"key":"824_CR48","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1345\/aph.1K009","volume":"41","author":"Yuan","year":"2007","unstructured":"Yuan CS (2007) Methylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects. Ann Pharmacother 41:984\u2013993","journal-title":"Ann Pharmacother"},{"key":"824_CR49","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1177\/0091270004273491","volume":"45","author":"Yuan","year":"2005","unstructured":"Yuan CS, Doshan H, Charney MR et al (2005) Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45:538\u2013546","journal-title":"J Clin Pharmacol"},{"key":"824_CR50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0028-3908(98)00192-0","volume":"38","author":"Yuan","year":"1999","unstructured":"Yuan CS, Foss JF (1999) Gastric effects of methylnaltrexone on mu, kappa, and delta opioid agonists induced brainstem unitary responses. Neuropharmacology 38:425\u2013432","journal-title":"Neuropharmacology"},{"key":"824_CR51","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/jama.284.11.1383","volume":"284","author":"Yuan","year":"2000","unstructured":"Yuan CS, Foss JF (2000) Oral methylnaltrexone for opioid-induced constipation. JAMA 284:1383\u20131384","journal-title":"JAMA"},{"key":"824_CR52","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1517\/13543784.15.5.541","volume":"15","author":"Yuan","year":"2006","unstructured":"Yuan CS, Israel RJ (2006) Methylnaltrexone, a novel peripheral opioid receptor antagonist for the treatment of opioid side effects. Expert Opin Investig Drugs 15:541\u2013552","journal-title":"Expert Opin Investig Drugs"},{"key":"824_CR53","first-page":"715","volume":"15","author":"Zhukovsky","year":"2007","unstructured":"Zhukovsky D, Slatkin N, Thomas J et al (2007) Methylnaltrexone for the treament of opioid-induced constipation in patients with advanced illness: evaluating the risk of central opioid antagonism in patients with CNS metastases. Support Care Cancer 15:715","journal-title":"Support Care Cancer"},{"key":"824_CR54","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1126\/science.1060952","volume":"293","author":"Zubieta","year":"2001","unstructured":"Zubieta JK, Smith YR, Bueller JA et al (2001) Regional mu opioid receptor regulation of sensory and affective dimensions of pain. Science 293:311\u2013315","journal-title":"Science"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-009-0824-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00482-009-0824-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-009-0824-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T19:46:06Z","timestamp":1739303166000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00482-009-0824-3"}},"subtitle":["Ein neuer Ansatz zur Therapie der opioidinduzierten Obstipation","A new approach for therapy of opioid-induced obstipation"],"short-title":[],"issued":{"date-parts":[[2009,8,20]]},"references-count":54,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009,10]]}},"alternative-id":["824"],"URL":"https:\/\/doi.org\/10.1007\/s00482-009-0824-3","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"type":"print","value":"0932-433X"},{"type":"electronic","value":"1432-2129"}],"subject":[],"published":{"date-parts":[[2009,8,20]]}}}